ISRG — Intuitive Surgical, Inc.

As of 2026-10-21, sentiment is neutral-to-cautious: shares fell 5.27% to $414.93 despite Q3 2026 revenue growth of 22% and non-GAAP EPS of $3.00 versus $2.65 consensus, because GAAP EPS was hit by a $450M antitrust settlement, procedure guidance was narrowed, and management flagged a 3-5% instruments revenue-per-procedure headwind from extended-use and China pricing. Analysts remain constructive—consensus Buy with a $485.50 target—but the stock sits 7.95% below its 200-day SMA and is down 16.72% over six months.

The 3-year trend is strong and stable-to-accelerating, not deteriorating. Revenue rose from $1.93B in Q4 2023 to $3.05B in Q3 2026, with latest-quarter growth of 21.7% YoY, following 18.5% in Q2 2026 and 23.0% in Q1 2026. Gross margin improved to 68.4% in Q3 2026 from 66.3% a year earlier, and the reported operating margin collapse to 19.4% is entirely due to the $450M litigation charge; excluding it, operating margin was roughly 34.2%, up from 30.3% in Q3 2025. GAAP EPS of $1.49 is a one-off distortion—non-GAAP EPS was $3.00—and free cash flow remains robust at $948M in Q2 2026, $809M in Q1 2026, and $730M in Q4 2025.

As of 2026-10-21, shares at $414.93 trade at 49.6x TTM EPS, 38.4x next-FY EPS of $10.805, 12.7x sales, and 5.6x TTM PEG; those are high absolute multiples, but below the 5-year average P/E of 72.6x and P/S of 19.3x. For a debt-free 20%+ revenue grower with 67% gross margin and 34%-ish ex-charge operating margin, valuation is fair-to-cheap versus its own history—not cheap on an absolute basis.

As of 2026-10-21, the $414.93 price is about 38x next-FY EPS, so the market is pricing high-teens/20% growth but not the 50-70x multiples of the zero-rate era. Q3 2026 beat on revenue and non-GAAP EPS, yet the stock fell 5.27% because GAAP EPS absorbed a $450M settlement and 2027 pricing/extended-use headwinds could reduce instruments revenue per procedure by 3-5%. The one-off charge should be ignored; the pricing headwind is real and may cap the multiple until 2027 guidance clarifies procedure growth and revenue per procedure.

As of 2026-10-21, RSI was 46.55—neutral, not oversold—with the price 2.9% below its 20-day SMA, 2.3% above its 50-day SMA, and 7.95% below its 200-day SMA. The 6-month return was -16.72% versus +18.21% over three months, so the medium-term trend is repairing but not confirmed. Entry-timing implication: the post-earnings drop offers a better entry than the pre-print level, but there is no technical urgency until the stock stabilizes or reclaims the 200-day SMA.

• Hospital capital spending remains pressured by higher-for-longer rates and budget scrutiny, making leasing flexibility and installation timing important for system placements.
• China’s operating environment is explicitly challenging, and targeted pricing actions there are a direct headwind to international revenue per procedure.
• Reimbursement and regulatory scrutiny across medtech can affect procedure adoption, system approvals, and hospital purchasing behavior.
• Competitive surgical robotics entrants, including Medtronic Hugo and J&J Ottava, could pressure pricing over time even if ISRG remains the clear leader.
• Procedure growth is bifurcated: U.S. growth has moderated to roughly 10%, while international markets are growing around 20%, making geographic mix and FX relevant.

• Q4 2026 earnings on 2027-01-28 (estimated) and initial 2027 guidance, especially procedure growth, margin trajectory, and pricing impact.
• da Vinci 5 rollout velocity: 315 placements in Q3 2026 out of 546 total da Vinci systems, with a growing installed base of 12,094 systems.
• Ion endoluminal system scaling, with Q3 2026 procedures up 31% year-over-year.
• Clarity on the extended-use instrument program and China pricing actions, plus removal of the antitrust litigation overhang after the $450M settlement.

• Extended-use instruments and China pricing actions are expected to reduce instruments and accessories revenue per procedure by 3-5%, pressuring 2027 estimates.
• U.S. procedure growth has moderated to roughly 10%, and full-year 2026 da Vinci procedure growth guidance was narrowed to 14-15%.
• Hospital capital constraints and leasing/placement timing could slow system revenue and installed-base expansion.
• Competition in robotic surgery and reimbursement/regulatory changes could limit pricing power or adoption.
• At 38x forward EPS, the valuation leaves little room for execution misses or a slower procedure-growth trajectory.

ISRG remains a high-quality, debt-free robotic-surgery franchise with reaccelerating 22% revenue growth, 68% gross margin, and a recurring instrument/service flywheel; the ugly Q3 2026 GAAP print was a $450M litigation charge, not operating deterioration. At 38x forward EPS—below its 5-year average—the stock offers positive long-term risk/reward, but the 3-5% pricing headwind for 2027 and weak technicals argue for patience rather than chasing.

As of 2026-10-21, I applied a 44x forward P/E—justified by 20%+ revenue growth, 67% gross margin, roughly 34% ex-charge operating margin, and zero net debt—to next-FY consensus EPS of $10.805: 44 × 10.805 = $475.42. This is a growth-adjusted discount to ISRG’s 72.6x five-year average P/E and sits below the $485.50 analyst consensus target.